Accendra Health 2025 Revenue Hits $2.8B, EBITDA Slips to $90M in Q4
Accendra Health posted 2025 revenue of $2.8 billion, a 3% increase, while adjusted EBITDA totalled $375 million despite Q4 EBITDA falling to $90 million from $102.5 million. The company divested its products and services unit to focus on Byram and Apria home-based care and guided 2026 revenue of $2.55–2.65 billion.
1. 2025 Financial Results
Accendra Health reported full-year 2025 revenue of $2.8 billion, a 3% increase year-over-year. Q4 adjusted EBITDA declined to $90 million from $102.5 million last year, bringing the annual total to $375 million.
2. 2026 Guidance and Headwinds
The company expects 2026 revenue of $2.55 to $2.65 billion and adjusted EBITDA of $335 to $355 million after losing a large commercial payer, which is projected to reduce revenue by $300 million. Management also warned of inflationary product costs and stranded costs from its recent divestiture.
3. Strategic Refocus on Home-Based Care
After divesting its products and services business, Accendra is concentrating on its core home-based care brands, Byram and Apria, to drive growth and streamline operations.
4. Operational Priorities and Cash Flow
The firm plans to accelerate cost reduction initiatives and leverage its MyApria app for operational efficiency, targeting at least $100 million in free cash flow for 2026.